Efficacy safety intravenous sotalol termination paroxysmal supraventricular tachycardia Sotalol Versus Placebo Multicenter Study Group double-blind placebo-controlled crossover multicenter study efficacy safety single intravenous dose sotalol mg/kg minutes normal sinus rhythm paroxysmal supraventricular tachycardia SVT equal minutes Patients sotalol placebo initial treatment SVT crossover minutes total patients spontaneous SVT sotalol efficacy patients atrioventricular AV reentrant tachycardia important subgroup movement tachycardia accessory pathway retrograde conduction number patients rhythm result initial treatment sotalol group placebo group spontaneous induced tachycardia Sinus rhythm minutes patients first drug patients first placebo sotalol safety analysis patients total patients sotalol first treatment second treatment patients placebo total possible adverse effects patients sotalol versus placebo severe side effect hypotension termination drug administration placebo proarrhythmic effects 